US Patent Issued to Regeneron Pharmaceuticals on July 29 for "Materials and methods of treating MHC-I-opathy risk haplotypes" (New York Inventors)

ALEXANDRIA, Va., July 30 -- United States Patent no. 12,370,257, issued on July 29, was assigned to Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.).

"Materials and methods of treating MHC-I-opathy risk haplotypes" was invented by Sahar Gelfman (Tarrytown, N.Y.), Ann Ligocki (Tarrytown, N.Y.), Giovanni Coppola (Tarrytown, N.Y.), Aris Baras (Tarrytown, N.Y.), Arden Moscati (Tarrytown, N.Y.), Eli A. Stahl (Tarrytown, N.Y.), Jack A. Kosmicki (Tarrytown, N.Y.), Manuel Allen Revez Ferreira (Tarrytown, N.Y.) and Carmelo Romano (Tarrytown, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides methods of treating subjects having an immune disorder by administering to the subject a thera...